News and Insights

Defining and Demonstrating Value

Transparency Around Value to Support Rational Pricing Discussions

eyeforpharma

The issue of drug pricing has become a staple of the news cycle, with fresh headlines every few weeks spotlighting either the high cost of new breakthrough drugs like Sovaldi, or jaw-dropping price hikes for existing, popular products like the EpiPen. While these examples represent two very different sets of…

Taking the Leap into Provider-Owned Health Plans

Trustee Magazine

Provider-owned health plans are commanding a larger share of the strategic dialogue in hospital boardrooms. POHPs aren’t a new phenomenon. Emerging from a history of mixed success in the 1980s and ’90s, they have gained popularity as the industry moves from volume- to value-based payment and as risk shifts from…

Barriers to Realizing Biosimilars’ Potential

PM360

For quite some time, providers, public and private payers, policy-makers, pharmacy benefit managers and patients have hoped the arrival of biosimilars would usher in a new era of competitive drug prices. However, as the U.S. market prepares to welcome its second biosimilar, Celltrion’s Inflectra, the future of biosimilars in this…

Risk-Sharing Agreements in the EU and Considerations for Moving Forward

Pharmaceutical Technology Europe

Payers across the globe are becoming increasingly assertive regarding products whose costs aren’t in line with perceived performance—a trend that shows no signs of slowing down. In fact, Express Scripts, one on the largest pharmacy benefit managers (PBMs) in the United States, recently announced a plan that would link the…

Preparing for Population Health Management

eyeforpharma

Although there have been modest successes in “bending the cost curve,” healthcare spending in the U.S. continues to reach unprecedented heights.  Over the next decade, healthcare costs are on track to nearly double, going from $2.9 to $5.2 trillion.1  What’s worse is that while the U.S. spends far more per…

Reference Pricing on the Horizon

eyeforpharma

The progression toward value-based care has enormous implications for manufacturers, influencing change in everything from pipeline investments to sales strategy.  Two critical trends stemming from the move to value are the increasing role of the consumer, and demands for price and outcome transparency.  Tapping into both of these trends is…